Real-world effectiveness of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and advanced melanoma at BC Cancer
Journal of Oncology Pharmacy Practice
Published online on March 03, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionNivolumab has demonstrated promising survival outcomes in melanoma. Original dosing was 3 mg/kg (maximum 240 mg) intravenously (IV) every two weeks (Q2 W). Based on pharmacokinetic and pharmacodynamic studies demonstrating similar efficacy, 6 ...
IntroductionNivolumab has demonstrated promising survival outcomes in melanoma. Original dosing was 3 mg/kg (maximum 240 mg) intravenously (IV) every two weeks (Q2 W). Based on pharmacokinetic and pharmacodynamic studies demonstrating similar efficacy, 6 ...